Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Gains from Sales and Divestitures (2016 - 2024)

Historic Gains from Sales and Divestitures for Palisade Bio (PALI) over the last 8 years, with Q4 2024 value amounting to $23067.0.

  • Palisade Bio's Gains from Sales and Divestitures fell 6225.95% to $23067.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $23067.0, marking a year-over-year decrease of 6225.95%. This contributed to the annual value of $23067.0 for FY2024, which is 6225.95% down from last year.
  • Palisade Bio's Gains from Sales and Divestitures amounted to $23067.0 in Q4 2024, which was down 6225.95% from $61120.0 recorded in Q4 2023.
  • Over the past 5 years, Palisade Bio's Gains from Sales and Divestitures peaked at $61120.0 during Q4 2023, and registered a low of $3814.0 during Q4 2020.
  • Over the past 4 years, Palisade Bio's median Gains from Sales and Divestitures value was $12662.0 (recorded in 2023), while the average stood at $21002.3.
  • Per our database at Business Quant, Palisade Bio's Gains from Sales and Divestitures plummeted by 4400.0% in 2021 and then crashed by 6225.95% in 2024.
  • Over the past 4 years, Palisade Bio's Gains from Sales and Divestitures (Quarter) stood at $3814.0 in 2020, then increased by 10.12% to $4200.0 in 2021, then skyrocketed by 1355.24% to $61120.0 in 2023, then tumbled by 62.26% to $23067.0 in 2024.
  • Its last three reported values are $23067.0 in Q4 2024, $61120.0 for Q4 2023, and $34653.0 during Q3 2023.